The DOI matches its Crossref record; 148 of the 151 references it cites were found in a registry or an index; 54 of the 207 sources its claims cite were checked for support.
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Open accessAbstract
Hallucinogens are a loosely defined group of compounds including LSD, N,N-dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences. We are witnessing a renaissance of research interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and ex vivo, and the various molecular imaging studies with positron emission tomography (PET) or single photon emission computer tomography (SPECT). In general, molecular imaging can depict the uptake and binding distribution of labelled hallucinogenic compounds or their congeners in the brain, as was shown in an early PET study with N1-([11C]-methyl)-2-bromo-LSD ([11C]-MBL); displacement with the non-radioactive competitor ketanserin confirmed that the majority of [11C]-MBL specific binding was to serotonin 5-HT2A receptors. However, interactions at serotonin 5HT1A and other classes of receptors and pleotropic effects on second messenger pathways may contribute to the particular experiential phenomenologies of LSD and other hallucinogenic compounds. Other salient aspects of hallucinogen action include permeability to the blood–brain barrier, the rates of metabolism and elimination, and the formation of active metabolites. Despite the maturation of radiochemistry and molecular imaging in recent years, there has been only a handful of PET or SPECT studies of radiolabeled hallucinogens, most recently using the 5-HT2A/2C agonist N-(2[11CH3O]-methoxybenzyl)-2,5-dimethoxy- 4-bromophenethylamine ([11C]Cimbi-36). In addition to PET studies of target engagement at neuroreceptors and transporters, there is a small number of studies on the effects of hallucinogenic compounds on cerebral perfusion ([15O]-water) or metabolism ([18F]-fluorodeoxyglucose/FDG). There remains considerable scope for basic imaging research on the sites of interaction of hallucinogens and their cerebrometabolic effects; we expect that hybrid imaging with PET in conjunction with functional magnetic resonance imaging (fMRI) should provide especially useful for the next phase of this research.
Overview
CoChat Summary
TL;DR
This is a narrative review of in vitro, ex vivo, PET/SPECT, and perfusion/metabolic imaging studies of hallucinogens, with a particular focus on serotonin receptor pharmacology and brain target engagement. Across the literature summarized, hallucinogens are presented as chiefly 5-HT2A agonists, but with important contributions from other receptors, metabolism, and flow-metabolism coupling to their effects.
Key findings
- The review states that hallucinogens generally share agonism at 5-HT2A sites, but many also show high affinity at 5HT2C and 5HT1A receptors; for example, LSD had Ki values of 3 nM at 5HT1A, 4 nM at 5HT2A, and 15 nM at 5HT2C sites, while psilocin had Ki values of 49 nM at 5HT2A, 94 nM at 5HT2C, and 123 nM at 5HT1A sites.
- In human PET work, psilocybin/psilocin produced substantial 5HT2A occupancy: Madsen et al. reported occupancy as high as 76% at plasma psilocin around 100 nM, and Hasler et al. reported widespread 50% decreases in [18F]-altanserin uptake after 20 mg psilocybin in 11 healthy young male subjects.
- Imaging findings summarized include both increased and decreased cerebral activity depending on tracer and modality: psilocybin increased CMRglc by up to +25% in frontal cortex, anterior cingulate, and medial temporal cortex in one FDG PET study (n = 10), while ASL/SPECT studies often found reduced perfusion in widespread regions after psilocybin or mescaline.
- The review notes that radiolabeled hallucinogen studies are still sparse despite modern radiochemistry; it specifically highlights early [11C]-MBL PET showing cortical binding displaced by ketanserin, and says there remains “considerable scope” for further PET/SPECT and hybrid PET-fMRI research.
Methods
- Narrative review of published literature on hallucinogen binding in vitro and ex vivo, plus molecular imaging studies using PET and SPECT; the article also discusses a smaller number of studies of cerebral perfusion and metabolism.
- Evidence base spans animals and humans, including rats, mice, pigs, baboons, rabbits, monkeys, and healthy volunteers, as well as a clinical Ayahuasca study in patients with recurrent major depressive disorder.
- Main analyses discussed include receptor-binding displacement/affinity studies, autoradiography, PET/SPECT tracer studies, competition paradigms (e.g., [11C]-raclopride, [18F]-altanserin, [11C]-Cimbi-36), and FDG/ASL perfusion imaging.
Limitations
- The paper explicitly states that the molecular imaging literature on hallucinogens is “rather sparse,” with only a handful of PET/SPECT studies and some well-known hallucinogens “entirely uninvestigated” by molecular imaging.
- Several findings are presented as interpretive or tentative, including possible confounding by anesthesia, metabolite effects, or drug mis-injection in animal imaging studies; these caveats are stated in the text.
- By its own framing, this is a narrative review rather than a systematic review or meta-analysis; that limits the ability to draw pooled quantitative conclusions from the evidence presented.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 [11C]-Cimbi-36 (38) activity summed over the 45 min scan time in rat brain (right) overlaid on an MR template image in the horizontal plane (left). High activity in cortical regions, especially mPFC, moderate activity in striatal and hippocampal regions and low binding in cerebellum.](https://figures.cochat.ai/paper-figures/7b9930eac10a40ccaf77b666dc8f4fca/molecular-and-functional-imaging-studies-of-psychedelic-drug-action-in-animals-figure-4.jpg)

![Figure 6 Inverse Correlation of 5D-ASC Global Scale scores and [18F]-altanserin (39) apparent distribution volume [DV’]. Results of a voxel based correlation analysis (Δ 5D-ASC global vs. ΔDV’, threshold p < 0.005, uncorrected) using Statistical Parametric Mapping [105]. Reproduced with permission.](https://figures.cochat.ai/paper-figures/9569a3fbfefc446a971749e9573d99ea/molecular-and-functional-imaging-studies-of-psychedelic-drug-action-in-animals-figure-6.jpg)
![Figure 7 Mean parametric maps of the total distribution volume of 5-[11C]-MeO-DMT (47) in brain of groups of three pigs at baseline and after treatment with the irreversible MAO A/B inhibitor, pargyline. There was no evidence of potentiation of the tracer uptake by blockade of MAO, nor was the binding in ventral striatum displaceable in studies with ketanserin (7) pretreatment (Jensen and Cumming, unpublished observations).](https://figures.cochat.ai/paper-figures/6893b4bed847409db7773772b99ee74d/molecular-and-functional-imaging-studies-of-psychedelic-drug-action-in-animals-figure-7.jpg)
Verification
Claims the paper makes
47 Valid · 5 Not valid · 140 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A prohibition against hallucinogen research established in many countries the 1970s was until recently an impediment to progress in our understanding of the phenomenology and physiology of hallucinogen action [2,3];”
§ Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans > 1. Introduction Structurally diverse ergolines, phenylethylamines, and tryptamines known collectively as hallucinogens induce perceptual and affective changes, extending from sensory distortions (illusions) to sensing of non-existent objects (hallucinations), with varying degree of control over or insight into the altered state. The sites of hallucinogen binding and action in the central nervous system are amenable to study by molecular imaging with positron emission tomography (PET) or single photon emission computer tomography (SPECT), and can now be studied by functional magnetic resonance imaging (fMRI) of cerebral perfusion and connectivity [1]. A prohibition against hallucinogen research established in many countries the 1970s was until recently an impediment to progress in our understanding of the phenomenology and physiology of hallucinogen action [2,3]; PubMed hits for the search term “hallucinogen” peaked in 1974, troughed around 1990, and have sustained a high level since 2010. Analysis of the literature in the past decade shows a shift in emphasis from preclinical studies especially of lysergic acid diethylamide (LSD) (1) towards more clinical applications, especially involving psilocybin (2) [4]. Indeed, there is now considerable interest in exploring the psychotherapeutic potential of hallucinogens, with 13 trials of psilocybin (2) undertaken in 2020 alone [5]. The renewed exploration of hallucinogens in a therapeutic setting raises important ethical and scientific consideration, and highlights the need for basic research on the action of hallucinogens in human brain [6,7]. The only recent review on imaging of hallucinogen actions focusses mainly on the fMRI literature [8]. Given this background, we now present a narrative review of the present state of the molecular imaging literature on hallucinogenic molecules. We emphasize first the selectivity and affinity of hallucinogenic compounds for serotonin receptors in vitro, discuss their fitness as radioligands for autoradiographic binding studies, and finally review the rather sparse literature on PET and SPECT studies with hallucinogens. Our aim is to extract general principles from the available results, and identify topics for future research in this domain. While various ancient peoples knew about plant- and animal-derived hallucinogens, the modern era of interest in hallucinogens began with the accidental discovery of the mind-altering effects of the ergot derivative LSD (1) (Figure 1). The extraordinary nature of experiences provoked by hallucinogens naturally motivated scientists to seek an understanding of their psychopharmacology and mechanisms of action. Hallucinogens belong to a variety of structural classes, including ergolines, phenylethylamines, and tryptamines (Figure 1, Figure 2, Figure 3 and Figure 5). As presented below, there is a general agreement that hallucinogens of the psychedelics class are agonists at serotonin 5HT2A receptors; although drugs of diverse other pharmacological classes can also induce hallucinations, we mainly confine this review to serotoninergic substances. However, the full spectrum of a given hallucinogen’s action may well entail actions at other serotonin receptors as well as receptors of dopamine, noradrenaline, histamine, trace amines, and neurotransmitter uptake sites (e.g., [9,10]). The spectrum of target engagement must somehow account for the overlapping and distinct aspects of the phenomenologies of different hallucinogenic drugs. Indeed, small structural modifications of certain molecules can decisively influence their hallucinogenic potency. For example, unlike N,N-diethyltryptamine (N,N-DET, 3), the corresponding diethyl compound, 6-fluoro-N,N-diethyltryptamine (4) is without hallucinogenic action in humans [11]. Similarly, 2-bromo-LSD (BOL-148, 5), despite its engagement with serotonin 5HT2A receptors, does not evoke hallucinations [12], except perhaps in rare cases [13]. Recent investigation of this phenomenon indicated that halogenation of N,N-DET (3) did not alter its affinity for serotonin 5HT2A receptors or various other receptor types, but disabled the intracellular response to agonism, i.e., stimulation of phosphotidyl inositol (PI) turnover [14], which may be a necessary property of effective hallucinogens. However, hallucinogenic activity is not a simple binary phenomenon, but encompasses a range of visual and sensory experiences. For example, mescaline (6) tends to evoke a characteristic visual experience of “geometricization” of three-dimensional objects, as is depicted in certain Amerindian art traditions. Visual hallucinations hint at a pharmacological action in the visual cortex [15], which is a theme amenable to analysis using a neural network approach [16]. It remains unclear how the particulars of mescaline (6) pharmacology might account for its greater propensity to evoke a specific type of visual experience. Despite the broadly overlapping serotonin receptor binding profiles of hallucinogenic tryptamines, interactions at other receptor types may contribute to their overall psychopharmacology or the particular phenomenology of hallucinogenic experiences [17]. Indeed, pretreatment of volunteers with the selective 5HT2A/C antagonist ketanserin (7), while largely abolishing the hallucinations elicited by psilocybin (2), did not attenuate binocular rivalry switching [18] or effects on attentional tracking performance [19]. Furthermore, a compilation of reports for a broad range of substances shows that interactions of serotonin, dopamine, glutamate, and opioid receptors all contribute to aspects of the subjective experience [20]. Other relevant factors for psychedelic action include the relationship between plasma kinetics of a drug, permeability for the blood–brain barrier, duration of target engagement in the central nervous system, and the intensity of psychedelic experience. Finally, the phenomena of “flashbacks” and hallucinogen-persisting perception disorder (HPPD) sometimes occurring in LSD (1) users [21] may call for reassessing the notion that visual hallucinations are only due to acute pharmacological activation of serotonin receptors [22]. The first phase of molecular imaging of hallucinogenic compounds employed in vitro binding techniques for assessing affinities and ex vivo methods for revealing the cerebral uptake and binding of radiopharmaceuticals in brain of living animals (e.g., [23]). Molecular imaging by positron emission tomography (PET) and single photon computer tomography (SPECT) have emerged in recent years as mature technologies for monitoring neuroreceptor availability in living brain, for measuring the extent of target engagement by psychoactive drugs [24,25], and to detect physiological responses of the brain to a pharmacological challenge. PET/SPECT methods are admirably suited for studying the cerebral uptake and binding of hallucinogens and for testing effects of psychoactive compounds on physiological markers such as the cerebral metabolic rate for glucose (CMRglc) or cerebral blood flow (CBF). However, this literature is rather sparse; indeed, some well-known hallucinogens remain entirely uninvestigated by molecular imaging techniques.
What the sources say
- Partly supportedcites [2] Petranker, 2020, Psychedelic Research and the Need for Transparency: Polishing Alice’s Looking Glass, Front. Psychol. sourceExperimental — accuracy not yet measured
The Brief History section says psychedelics were globally prohibited in 1971 and that prohibition suppressed psychedelic-research publication rates for decades. It also describes a twenty-first-century research resurgence. The paper does not specifically say that prohibition impeded understanding of both the phenomenology and physiology of hallucinogen action. (LLM, conf=0.85)
- Not checked yetcites [3] Doblin, 2019, The Past and Future of Psychedelic Science: An Introduction to This Issue, J. Psychoact. Drugs source
Checked before — its earlier verdict is held back until a new check runs.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the full spectrum of a given hallucinogen’s action may well entail actions at other serotonin receptors as well as receptors of dopamine, noradrenaline, histamine, trace amines, and neurotransmitter uptake sites (e.g., [9,10]).”
§ Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans > 1. Introduction Structurally diverse ergolines, phenylethylamines, and tryptamines known collectively as hallucinogens induce perceptual and affective changes, extending from sensory distortions (illusions) to sensing of non-existent objects (hallucinations), with varying degree of control over or insight into the altered state. The sites of hallucinogen binding and action in the central nervous system are amenable to study by molecular imaging with positron emission tomography (PET) or single photon emission computer tomography (SPECT), and can now be studied by functional magnetic resonance imaging (fMRI) of cerebral perfusion and connectivity [1]. A prohibition against hallucinogen research established in many countries the 1970s was until recently an impediment to progress in our understanding of the phenomenology and physiology of hallucinogen action [2,3]; PubMed hits for the search term “hallucinogen” peaked in 1974, troughed around 1990, and have sustained a high level since 2010. Analysis of the literature in the past decade shows a shift in emphasis from preclinical studies especially of lysergic acid diethylamide (LSD) (1) towards more clinical applications, especially involving psilocybin (2) [4]. Indeed, there is now considerable interest in exploring the psychotherapeutic potential of hallucinogens, with 13 trials of psilocybin (2) undertaken in 2020 alone [5]. The renewed exploration of hallucinogens in a therapeutic setting raises important ethical and scientific consideration, and highlights the need for basic research on the action of hallucinogens in human brain [6,7]. The only recent review on imaging of hallucinogen actions focusses mainly on the fMRI literature [8]. Given this background, we now present a narrative review of the present state of the molecular imaging literature on hallucinogenic molecules. We emphasize first the selectivity and affinity of hallucinogenic compounds for serotonin receptors in vitro, discuss their fitness as radioligands for autoradiographic binding studies, and finally review the rather sparse literature on PET and SPECT studies with hallucinogens. Our aim is to extract general principles from the available results, and identify topics for future research in this domain. While various ancient peoples knew about plant- and animal-derived hallucinogens, the modern era of interest in hallucinogens began with the accidental discovery of the mind-altering effects of the ergot derivative LSD (1) (Figure 1). The extraordinary nature of experiences provoked by hallucinogens naturally motivated scientists to seek an understanding of their psychopharmacology and mechanisms of action. Hallucinogens belong to a variety of structural classes, including ergolines, phenylethylamines, and tryptamines (Figure 1, Figure 2, Figure 3 and Figure 5). As presented below, there is a general agreement that hallucinogens of the psychedelics class are agonists at serotonin 5HT2A receptors; although drugs of diverse other pharmacological classes can also induce hallucinations, we mainly confine this review to serotoninergic substances. However, the full spectrum of a given hallucinogen’s action may well entail actions at other serotonin receptors as well as receptors of dopamine, noradrenaline, histamine, trace amines, and neurotransmitter uptake sites (e.g., [9,10]). The spectrum of target engagement must somehow account for the overlapping and distinct aspects of the phenomenologies of different hallucinogenic drugs. Indeed, small structural modifications of certain molecules can decisively influence their hallucinogenic potency. For example, unlike N,N-diethyltryptamine (N,N-DET, 3), the corresponding diethyl compound, 6-fluoro-N,N-diethyltryptamine (4) is without hallucinogenic action in humans [11]. Similarly, 2-bromo-LSD (BOL-148, 5), despite its engagement with serotonin 5HT2A receptors, does not evoke hallucinations [12], except perhaps in rare cases [13]. Recent investigation of this phenomenon indicated that halogenation of N,N-DET (3) did not alter its affinity for serotonin 5HT2A receptors or various other receptor types, but disabled the intracellular response to agonism, i.e., stimulation of phosphotidyl inositol (PI) turnover [14], which may be a necessary property of effective hallucinogens. However, hallucinogenic activity is not a simple binary phenomenon, but encompasses a range of visual and sensory experiences. For example, mescaline (6) tends to evoke a characteristic visual experience of “geometricization” of three-dimensional objects, as is depicted in certain Amerindian art traditions. Visual hallucinations hint at a pharmacological action in the visual cortex [15], which is a theme amenable to analysis using a neural network approach [16]. It remains unclear how the particulars of mescaline (6) pharmacology might account for its greater propensity to evoke a specific type of visual experience. Despite the broadly overlapping serotonin receptor binding profiles of hallucinogenic tryptamines, interactions at other receptor types may contribute to their overall psychopharmacology or the particular phenomenology of hallucinogenic experiences [17]. Indeed, pretreatment of volunteers with the selective 5HT2A/C antagonist ketanserin (7), while largely abolishing the hallucinations elicited by psilocybin (2), did not attenuate binocular rivalry switching [18] or effects on attentional tracking performance [19]. Furthermore, a compilation of reports for a broad range of substances shows that interactions of serotonin, dopamine, glutamate, and opioid receptors all contribute to aspects of the subjective experience [20]. Other relevant factors for psychedelic action include the relationship between plasma kinetics of a drug, permeability for the blood–brain barrier, duration of target engagement in the central nervous system, and the intensity of psychedelic experience. Finally, the phenomena of “flashbacks” and hallucinogen-persisting perception disorder (HPPD) sometimes occurring in LSD (1) users [21] may call for reassessing the notion that visual hallucinations are only due to acute pharmacological activation of serotonin receptors [22]. The first phase of molecular imaging of hallucinogenic compounds employed in vitro binding techniques for assessing affinities and ex vivo methods for revealing the cerebral uptake and binding of radiopharmaceuticals in brain of living animals (e.g., [23]). Molecular imaging by positron emission tomography (PET) and single photon computer tomography (SPECT) have emerged in recent years as mature technologies for monitoring neuroreceptor availability in living brain, for measuring the extent of target engagement by psychoactive drugs [24,25], and to detect physiological responses of the brain to a pharmacological challenge. PET/SPECT methods are admirably suited for studying the cerebral uptake and binding of hallucinogens and for testing effects of psychoactive compounds on physiological markers such as the cerebral metabolic rate for glucose (CMRglc) or cerebral blood flow (CBF). However, this literature is rather sparse; indeed, some well-known hallucinogens remain entirely uninvestigated by molecular imaging techniques.
What the sources say
- Not checked — no full text of the sourcecites [9] Rickli, 2016, Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens, Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. source
- Partly supportedcites [10] McKenna, 1989, Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin, J. Neurosci. sourceExperimental — accuracy not yet measured
The Discussion (page not provided) links hallucinogen affinity for a serotonin-receptor subtype with human hallucinogenic doses, supporting a possible serotonin-receptor role. Our copy does not link hallucinogens’ broader effects to dopamine, noradrenaline, histamine or trace-amine receptors, or to neurotransmitter uptake sites. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, the mouse head-twitch response behavioral paradigm and rat trials of drug discrimination may serve better to predict hallucinogenic potency of drugs in humans [28].”
§ Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans > 2. Binding Sites of Hallucinogens In Vitro > 2.1. The Nature of Agonist-Receptor Interactions Agonism at serotonin receptors is an essential property of hallucinogens. Most serotonin receptors couple to intracellular second messenger systems by one or more guanine nucleotide binding proteins (G-proteins); the presence of guanosine triphosphate (GTP) or its metabolically stable analogues in the receptor binding assay disfavors the binding of agonist ligands, but has no effect on antagonist binding. Thus, the addition of GTP to a binding assay causes a substantial loss of affinity of an agonist ligand in vitro, manifesting in a shift to the right of a displacement curve against the bonding of a labelled antagonist ligand. In general, agonist binding stimulates GTP/GDP exchange, which results in activation of the enzyme adenylate cyclase in the case of the Gs-type G-protein, inhibition of adenylyl cyclase in the case of Gi/o, and stimulation of phospholipase C in the case of Gq/11, among many possible signal transduction pathways. For example, agonists of 5HT1A sites such as 8-hydroxy-DPAT have no intrinsic effect on cyclic AMP (cAMP) production in rat hippocampal neurons, but inhibit the stimulation of adenylyl cyclase provoked by other receptor types [26], thus suggesting receptor coupling to second messenger systems via Gi/o-type G-proteins. In another assay system, the increased retention of [35S]-guanosine-5-O-(3-thio)-triphosphate in membranes reveals agonist interactions. Indeed, that assay may serve as a forensic tool for operationally predicting the hallucinogenic properties of members of a series of tryptamine derivatives [27]. However, the mouse head-twitch response behavioral paradigm and rat trials of drug discrimination may serve better to predict hallucinogenic potency of drugs in humans [28]. While the preponderance of evidence indicates that 5HT2A agonism is a necessary property of hallucinogens, this is not sufficient, since certain 5-HT2A receptor agonists such as lisuride (21) and ergotamine (22) (Figure 2) do not evoke hallucinations (e.g., [29]). Explaining this phenomenon may call for arguments from non-classical pharmacology, whereby agonists can engage different signal transduction pathways through the same receptor. Serotonin 5HT2A receptors typically couple to the Gq/11-mediated signaling pathway, which activates phospholipase C (PLC) to stimulate the formation of inositol phosphates and diacylglycerol, leading to Ca2+ release from the endoplasmic reticulum [30]. Although some hallucinogens only weakly stimulate this pathway, hallucinogenic potency may correlate with the efficacy in activating PLC [31]. On the other hand, LSD (1) was more effective at activating the 5HT2A/2C-coupled phospholipase A2 (PLA2) pathway that mediates arachidonic acid release, whereas the non-hallucinogenic compound 3-trifluoromethylphenyl-piperazine preferentially activated the PLC-IP pathway [32]. Hallucinogenic effects at 5HT2A receptors may also entail activation of the pertussis toxin (PTX)-sensitive heterotrimeric Gi/o proteins [33]. As such, it may be the second messenger pathways rather than the particular receptor targets that mediate psychedelic action. Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34]; this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) noted above. Certainly, the 5HT2A/mGluR2 dimer adds an additional level of complexity to the mechanism of action of hallucinogens. In the special case of presynaptic autoreceptors, silencing of neuronal electrical activity upon drug application is a functional indicator of agonism. Early electrophysiological research showed that administration of LSD (1) at a low dose (5–10 µg/kg) provoked silencing of serotonin neurons in the rat dorsal raphé [35], presumably via activation of 5HT1A autoreceptors. Various other hallucinogenic compounds (psilocin (8), N,N-dimethyltryptamine [DMT (9)], and bufotenin (10)) inhibit serotonin neuron activity with a potency following the rank order of their potency as hallucinogens [36]. In electrophysiological studies, treatment with 5-HT1A receptor antagonist WAY-100,635 (500 μg/kg, i.v.) prevented the inhibitory effect of LSD (1) on the firing rate of dopaminergic ventral tegmental neurons in the rat brain [37]. In the same study, treatment with a blocker of the trace amine-associated receptor (TAAR) type 1 also interfered in the effects of LSD (1) on dopamine neuron activity. In vitro binding competition studies indicated that LSD (1) and other hallucinogens possess some affinity for TAAR1 [9].
What the sources say
- Supportedcites [28] Halberstadt, 2020, Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species, Neuropharmacology source
The Discussion states that mouse head-twitch responses and rat drug-discrimination results correlate strongly with reported human hallucinogen potencies, supporting their predictive validity. It specifically endorses using the head-twitch paradigm to predict potency in humans. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, a compilation of reports for a broad range of substances shows that interactions of serotonin, dopamine, glutamate, and opioid receptors all contribute to aspects of the subjective experience [20].”
§ Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans > 1. Introduction Structurally diverse ergolines, phenylethylamines, and tryptamines known collectively as hallucinogens induce perceptual and affective changes, extending from sensory distortions (illusions) to sensing of non-existent objects (hallucinations), with varying degree of control over or insight into the altered state. The sites of hallucinogen binding and action in the central nervous system are amenable to study by molecular imaging with positron emission tomography (PET) or single photon emission computer tomography (SPECT), and can now be studied by functional magnetic resonance imaging (fMRI) of cerebral perfusion and connectivity [1]. A prohibition against hallucinogen research established in many countries the 1970s was until recently an impediment to progress in our understanding of the phenomenology and physiology of hallucinogen action [2,3]; PubMed hits for the search term “hallucinogen” peaked in 1974, troughed around 1990, and have sustained a high level since 2010. Analysis of the literature in the past decade shows a shift in emphasis from preclinical studies especially of lysergic acid diethylamide (LSD) (1) towards more clinical applications, especially involving psilocybin (2) [4]. Indeed, there is now considerable interest in exploring the psychotherapeutic potential of hallucinogens, with 13 trials of psilocybin (2) undertaken in 2020 alone [5]. The renewed exploration of hallucinogens in a therapeutic setting raises important ethical and scientific consideration, and highlights the need for basic research on the action of hallucinogens in human brain [6,7]. The only recent review on imaging of hallucinogen actions focusses mainly on the fMRI literature [8]. Given this background, we now present a narrative review of the present state of the molecular imaging literature on hallucinogenic molecules. We emphasize first the selectivity and affinity of hallucinogenic compounds for serotonin receptors in vitro, discuss their fitness as radioligands for autoradiographic binding studies, and finally review the rather sparse literature on PET and SPECT studies with hallucinogens. Our aim is to extract general principles from the available results, and identify topics for future research in this domain. While various ancient peoples knew about plant- and animal-derived hallucinogens, the modern era of interest in hallucinogens began with the accidental discovery of the mind-altering effects of the ergot derivative LSD (1) (Figure 1). The extraordinary nature of experiences provoked by hallucinogens naturally motivated scientists to seek an understanding of their psychopharmacology and mechanisms of action. Hallucinogens belong to a variety of structural classes, including ergolines, phenylethylamines, and tryptamines (Figure 1, Figure 2, Figure 3 and Figure 5). As presented below, there is a general agreement that hallucinogens of the psychedelics class are agonists at serotonin 5HT2A receptors; although drugs of diverse other pharmacological classes can also induce hallucinations, we mainly confine this review to serotoninergic substances. However, the full spectrum of a given hallucinogen’s action may well entail actions at other serotonin receptors as well as receptors of dopamine, noradrenaline, histamine, trace amines, and neurotransmitter uptake sites (e.g., [9,10]). The spectrum of target engagement must somehow account for the overlapping and distinct aspects of the phenomenologies of different hallucinogenic drugs. Indeed, small structural modifications of certain molecules can decisively influence their hallucinogenic potency. For example, unlike N,N-diethyltryptamine (N,N-DET, 3), the corresponding diethyl compound, 6-fluoro-N,N-diethyltryptamine (4) is without hallucinogenic action in humans [11]. Similarly, 2-bromo-LSD (BOL-148, 5), despite its engagement with serotonin 5HT2A receptors, does not evoke hallucinations [12], except perhaps in rare cases [13]. Recent investigation of this phenomenon indicated that halogenation of N,N-DET (3) did not alter its affinity for serotonin 5HT2A receptors or various other receptor types, but disabled the intracellular response to agonism, i.e., stimulation of phosphotidyl inositol (PI) turnover [14], which may be a necessary property of effective hallucinogens. However, hallucinogenic activity is not a simple binary phenomenon, but encompasses a range of visual and sensory experiences. For example, mescaline (6) tends to evoke a characteristic visual experience of “geometricization” of three-dimensional objects, as is depicted in certain Amerindian art traditions. Visual hallucinations hint at a pharmacological action in the visual cortex [15], which is a theme amenable to analysis using a neural network approach [16]. It remains unclear how the particulars of mescaline (6) pharmacology might account for its greater propensity to evoke a specific type of visual experience. Despite the broadly overlapping serotonin receptor binding profiles of hallucinogenic tryptamines, interactions at other receptor types may contribute to their overall psychopharmacology or the particular phenomenology of hallucinogenic experiences [17]. Indeed, pretreatment of volunteers with the selective 5HT2A/C antagonist ketanserin (7), while largely abolishing the hallucinations elicited by psilocybin (2), did not attenuate binocular rivalry switching [18] or effects on attentional tracking performance [19]. Furthermore, a compilation of reports for a broad range of substances shows that interactions of serotonin, dopamine, glutamate, and opioid receptors all contribute to aspects of the subjective experience [20]. Other relevant factors for psychedelic action include the relationship between plasma kinetics of a drug, permeability for the blood–brain barrier, duration of target engagement in the central nervous system, and the intensity of psychedelic experience. Finally, the phenomena of “flashbacks” and hallucinogen-persisting perception disorder (HPPD) sometimes occurring in LSD (1) users [21] may call for reassessing the notion that visual hallucinations are only due to acute pharmacological activation of serotonin receptors [22]. The first phase of molecular imaging of hallucinogenic compounds employed in vitro binding techniques for assessing affinities and ex vivo methods for revealing the cerebral uptake and binding of radiopharmaceuticals in brain of living animals (e.g., [23]). Molecular imaging by positron emission tomography (PET) and single photon computer tomography (SPECT) have emerged in recent years as mature technologies for monitoring neuroreceptor availability in living brain, for measuring the extent of target engagement by psychoactive drugs [24,25], and to detect physiological responses of the brain to a pharmacological challenge. PET/SPECT methods are admirably suited for studying the cerebral uptake and binding of hallucinogens and for testing effects of psychoactive compounds on physiological markers such as the cerebral metabolic rate for glucose (CMRglc) or cerebral blood flow (CBF). However, this literature is rather sparse; indeed, some well-known hallucinogens remain entirely uninvestigated by molecular imaging techniques.
What the sources say
- Partly supportedcites [20] Zamberlan, 2018, The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines, Front. Integr. Neurosci. sourceExperimental — accuracy not yet measured
The Abstract and Results report that, across psychedelic phenethylamines and tryptamines, binding affinities involving serotonin, dopamine, glutamate, and opioid receptors helped predict similarities in reported subjective effects (page numbers unavailable). The paper calls this preliminary, correlational evidence; it does not establish that interactions at each receptor type causally contribute to experience across a broad range of substances. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34];”
§ Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans > 2. Binding Sites of Hallucinogens In Vitro > 2.1. The Nature of Agonist-Receptor Interactions Agonism at serotonin receptors is an essential property of hallucinogens. Most serotonin receptors couple to intracellular second messenger systems by one or more guanine nucleotide binding proteins (G-proteins); the presence of guanosine triphosphate (GTP) or its metabolically stable analogues in the receptor binding assay disfavors the binding of agonist ligands, but has no effect on antagonist binding. Thus, the addition of GTP to a binding assay causes a substantial loss of affinity of an agonist ligand in vitro, manifesting in a shift to the right of a displacement curve against the bonding of a labelled antagonist ligand. In general, agonist binding stimulates GTP/GDP exchange, which results in activation of the enzyme adenylate cyclase in the case of the Gs-type G-protein, inhibition of adenylyl cyclase in the case of Gi/o, and stimulation of phospholipase C in the case of Gq/11, among many possible signal transduction pathways. For example, agonists of 5HT1A sites such as 8-hydroxy-DPAT have no intrinsic effect on cyclic AMP (cAMP) production in rat hippocampal neurons, but inhibit the stimulation of adenylyl cyclase provoked by other receptor types [26], thus suggesting receptor coupling to second messenger systems via Gi/o-type G-proteins. In another assay system, the increased retention of [35S]-guanosine-5-O-(3-thio)-triphosphate in membranes reveals agonist interactions. Indeed, that assay may serve as a forensic tool for operationally predicting the hallucinogenic properties of members of a series of tryptamine derivatives [27]. However, the mouse head-twitch response behavioral paradigm and rat trials of drug discrimination may serve better to predict hallucinogenic potency of drugs in humans [28]. While the preponderance of evidence indicates that 5HT2A agonism is a necessary property of hallucinogens, this is not sufficient, since certain 5-HT2A receptor agonists such as lisuride (21) and ergotamine (22) (Figure 2) do not evoke hallucinations (e.g., [29]). Explaining this phenomenon may call for arguments from non-classical pharmacology, whereby agonists can engage different signal transduction pathways through the same receptor. Serotonin 5HT2A receptors typically couple to the Gq/11-mediated signaling pathway, which activates phospholipase C (PLC) to stimulate the formation of inositol phosphates and diacylglycerol, leading to Ca2+ release from the endoplasmic reticulum [30]. Although some hallucinogens only weakly stimulate this pathway, hallucinogenic potency may correlate with the efficacy in activating PLC [31]. On the other hand, LSD (1) was more effective at activating the 5HT2A/2C-coupled phospholipase A2 (PLA2) pathway that mediates arachidonic acid release, whereas the non-hallucinogenic compound 3-trifluoromethylphenyl-piperazine preferentially activated the PLC-IP pathway [32]. Hallucinogenic effects at 5HT2A receptors may also entail activation of the pertussis toxin (PTX)-sensitive heterotrimeric Gi/o proteins [33]. As such, it may be the second messenger pathways rather than the particular receptor targets that mediate psychedelic action. Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34]; this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) noted above. Certainly, the 5HT2A/mGluR2 dimer adds an additional level of complexity to the mechanism of action of hallucinogens. In the special case of presynaptic autoreceptors, silencing of neuronal electrical activity upon drug application is a functional indicator of agonism. Early electrophysiological research showed that administration of LSD (1) at a low dose (5–10 µg/kg) provoked silencing of serotonin neurons in the rat dorsal raphé [35], presumably via activation of 5HT1A autoreceptors. Various other hallucinogenic compounds (psilocin (8), N,N-dimethyltryptamine [DMT (9)], and bufotenin (10)) inhibit serotonin neuron activity with a potency following the rank order of their potency as hallucinogens [36]. In electrophysiological studies, treatment with 5-HT1A receptor antagonist WAY-100,635 (500 μg/kg, i.v.) prevented the inhibitory effect of LSD (1) on the firing rate of dopaminergic ventral tegmental neurons in the rat brain [37]. In the same study, treatment with a blocker of the trace amine-associated receptor (TAAR) type 1 also interfered in the effects of LSD (1) on dopamine neuron activity. In vitro binding competition studies indicated that LSD (1) and other hallucinogens possess some affinity for TAAR1 [9].
What the sources say
- Partly supportedcites [34] Ang, 2008, Identification of a serotonin/glutamate receptor complex implicated in psychosis, Nature sourceExperimental — accuracy not yet measured
The passages describing the binding experiments and functional assays report allosteric effects on serotonin-agonist binding and signaling by the 2AR/mGluR2 complex. The passage on molecular chimeras calls the heterodimer a predicted model and says larger oligomers are not excluded, so the definitive description of the complex as a heterodimer goes beyond what the paper establishes. The supplied passages are labeled Abstract and have no page numbers. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
129 more claims · 24 with their cited sources checked
Create a free account to see all 245 claims and to verify the 22 references still open.
- It may state two separate claims as one. 104
- Probably not a substantial claim. 11
- The quote only partly states this claim. 1
Citations
Cites
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Molecular biology of 5-HT receptors
Hannon, J., & Hoyer, D. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.03.020 · Cited by 815 · cited 1×
“Serotonin 5HT2A receptors typically couple to the Gq/11-mediated signaling pathway, which activates phospholipase C (PLC) to stimulate the formation of inositol phosphates and diacylglycerol, leading to Ca2+ release from the endoplasmic reticulum [30].”
BackgroundIdentification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803 · cited 1×
“Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34]; this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) not…”
BackgroundPsilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 2×
“However, a single dose of psilocybin (2) provoked in healthy individuals a long-lasting increase in scores for the personality traits of openness to experience and mindfulness, which correlated inversely with reductions in [11C]-Cimbi-36 (38) binding [106].”
Background
Research works printed but not linked: 2
- Shulgin, A.T., and Shulgin, A. (1997). THIKAL, The Continuation, Transform Press.
- Hasler, 2009, Role of prefrontal serotonin-2A receptors in self experience during pilocybin-indiced altered states, Neuropsychobiology, 59, 60
Cited by
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 57
“For example, after administratio of mescaline (5–10 mg/kg), some subjects perceived time faster and others slower [85,90,92,94,95,99].”
BackgroundNeuroimaging in psychedelic drug development: past, present, and future
Wall, M. B., Harding, R., Zafar, R. R., Rabiner, E. A., Nutt, D. J., & Erritzøe, D. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02271-0 · Cited by 46
“The utility of radioli-gands such as [18F]setoperone, [18F]altanserine and [11C] MDL100907 was limited by the methodological issues inherent in the evaluation of agonist compounds using antagonist PET radioligands [31].”
Berlowitz, I., Egger, K., & Cumming, P. D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.886408 · Cited by 47
“…to potentiate central action of the hallucinogenic component N,N-dimethyltryptamine (DMT), which is a hallucinogenic serotonin 5-HT2A agonist otherwise subject to rapid deamination in the gut following oral administration (Cumming, 2021), as attested by a series of selfexperiments (Ott, 1999).”
BackgroundSelf-citationCastelhano, J., Lima, G., Teixeira, M., Soares, C., Pais, M. L., & Castelo-Branco, M. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739053 · Cited by 48
“Rigorous research (possibly integrating PET with fMRI (Cumming et al., 2021)) is needed, taking into account the best clinical practices.”
Background
Metadata
- Authors
- Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C.
- Affiliations
- Queensland University of Technology (AU)
- University of Zurich (CH)
- University of Southern Denmark (DK)
- Department of Psychology, University of Fribourg, CH-1700 Fribourg, Switzerland
- Corresponding author
- Cumming, Paul
- ORCID
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-04-22
- Volume
- 26
- Issue
- 9
- Pages
- 2451
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8122807
- OpenAlex
- W3153638782
- Cited by
- 43
- References
- 151
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 11 · 2023: 9 · 2022: 12 · 2021: 2
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
- QUT ePrints (Queensland University of Technology) (submittedVersion, cc-by)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- ETH Zürich Research Collection (cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Keywords
- hallucinogens, psychedelics, 5-HT2A receptor, 5-HT1A receptor, PET radiotracer, blood-brain barrier permeability, cerebral perfusion, brain glucose metabolism
- MeSH terms
- Clinical Studies as Topic, Animals, Carrier Proteins, Cerebrovascular Circulation, Drug Evaluation, Preclinical, Energy Metabolism, Hallucinogens, Humans, Image Processing, Computer-Assisted, Protein Binding, Molecular Structure, Biomarkers, Tomography, Emission-Computed, Single-Photon, Drug Monitoring, Positron-Emission Tomography, Molecular Imaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. https://app.cochat.ai/papers/10.3390/molecules26092451
- The paper
- Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021). Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. Molecules. https://doi.org/10.3390/molecules26092451
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.